Lupin receives USFDA approval for Sildenafil for Oral Suspension; Stock ends 3.5% higher

24 Mar 2022 , 03:45 PM

Global pharma major Lupin Limited on Thursday has announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL to market a generic equivalent of Revatio for Oral Suspension, 10 mg/mL, of Viatris Specialty LLC.

The product will be manufactured at Lupin’s facility in Goa, India, said company.

Sildenafil for Oral Suspension, 10 mg/mL (RLD Revatio had estimated annual sales of USD 66 million in the U.S. (IQVIA MAT December 2021).

On Thursday, Lupin ended at Rs773.90 per share higher by 3.59% on Sensex.